DE69630055D1 - Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation - Google Patents
Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardationInfo
- Publication number
- DE69630055D1 DE69630055D1 DE69630055T DE69630055T DE69630055D1 DE 69630055 D1 DE69630055 D1 DE 69630055D1 DE 69630055 T DE69630055 T DE 69630055T DE 69630055 T DE69630055 T DE 69630055T DE 69630055 D1 DE69630055 D1 DE 69630055D1
- Authority
- DE
- Germany
- Prior art keywords
- olanzapine
- autism
- medicine
- salt
- mental retardation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Chemical Treatment Of Metals (AREA)
- Transplanting Machines (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Luminescent Compositions (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1316296P | 1996-03-11 | 1996-03-11 | |
| US13162P | 1996-03-11 | ||
| PCT/US1996/019576 WO1997033585A1 (en) | 1996-03-11 | 1996-12-04 | Method for treating autism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69630055D1 true DE69630055D1 (de) | 2003-10-23 |
| DE69630055T2 DE69630055T2 (de) | 2004-06-03 |
Family
ID=21758619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69630055T Expired - Fee Related DE69630055T2 (de) | 1996-03-11 | 1996-12-04 | Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0946179B1 (de) |
| JP (1) | JP2000506860A (de) |
| KR (1) | KR19990087715A (de) |
| CN (1) | CN1213970A (de) |
| AT (1) | ATE249832T1 (de) |
| AU (1) | AU709181B2 (de) |
| BR (1) | BR9612552A (de) |
| CA (1) | CA2248741A1 (de) |
| CZ (1) | CZ290498A3 (de) |
| DE (1) | DE69630055T2 (de) |
| EA (1) | EA000768B1 (de) |
| ES (1) | ES2206614T3 (de) |
| HU (1) | HUP9903688A3 (de) |
| IL (1) | IL126161A0 (de) |
| NO (1) | NO984197L (de) |
| NZ (1) | NZ324615A (de) |
| PL (1) | PL328948A1 (de) |
| TR (1) | TR199801798T2 (de) |
| WO (1) | WO1997033585A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2237188T3 (es) * | 1998-11-23 | 2005-07-16 | Sepracor Inc. | Composiciones de desmetilolanzapina y metodos. |
| WO2000030648A1 (en) * | 1998-11-23 | 2000-06-02 | Sepracor Inc. | 2-hydroxymethylolanzapine compositions and methods |
| ATE253364T1 (de) * | 1998-11-23 | 2003-11-15 | Sepracor Inc | Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen |
| US9770423B2 (en) | 2012-07-22 | 2017-09-26 | Indiana University Research And Technology Corporation | Modulation sAPP, sAAPα and BDNF levels in individuals diagnosed with FXS and ASD |
| EP3058371B1 (de) | 2013-10-14 | 2021-06-16 | Indiana University Research and Technology Corporation | Verwendung von acamprosat zur modulierung der erk-1 2-aktivierung bei tiermodellen für fxs und asd und mit fxs und asd diagnostizierten personen |
| RU2666598C1 (ru) * | 2017-07-14 | 2018-09-11 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Средство для коррекции расстройств аутистического спектра |
| KR102285577B1 (ko) | 2020-11-11 | 2021-08-04 | 김의철 | 자폐를 가진 유소년의 무약물 치료방법 및 시스템 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225407A (en) * | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
| US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
-
1996
- 1996-12-04 CZ CZ982904A patent/CZ290498A3/cs unknown
- 1996-12-04 TR TR1998/01798T patent/TR199801798T2/xx unknown
- 1996-12-04 AT AT96942934T patent/ATE249832T1/de not_active IP Right Cessation
- 1996-12-04 AU AU11501/97A patent/AU709181B2/en not_active Ceased
- 1996-12-04 HU HU9903688A patent/HUP9903688A3/hu unknown
- 1996-12-04 IL IL12616196A patent/IL126161A0/xx unknown
- 1996-12-04 NZ NZ324615A patent/NZ324615A/xx unknown
- 1996-12-04 EA EA199800821A patent/EA000768B1/ru not_active IP Right Cessation
- 1996-12-04 BR BR9612552A patent/BR9612552A/pt not_active Application Discontinuation
- 1996-12-04 CN CN96180207A patent/CN1213970A/zh active Pending
- 1996-12-04 KR KR1019980707182A patent/KR19990087715A/ko not_active Application Discontinuation
- 1996-12-04 EP EP96942934A patent/EP0946179B1/de not_active Expired - Lifetime
- 1996-12-04 DE DE69630055T patent/DE69630055T2/de not_active Expired - Fee Related
- 1996-12-04 ES ES96942934T patent/ES2206614T3/es not_active Expired - Lifetime
- 1996-12-04 CA CA002248741A patent/CA2248741A1/en not_active Abandoned
- 1996-12-04 JP JP09532571A patent/JP2000506860A/ja not_active Withdrawn
- 1996-12-04 WO PCT/US1996/019576 patent/WO1997033585A1/en active IP Right Grant
- 1996-12-04 PL PL96328948A patent/PL328948A1/xx unknown
-
1998
- 1998-09-11 NO NO984197A patent/NO984197L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0946179B1 (de) | 2003-09-17 |
| CA2248741A1 (en) | 1997-09-18 |
| ATE249832T1 (de) | 2003-10-15 |
| CZ290498A3 (cs) | 1999-10-13 |
| WO1997033585A1 (en) | 1997-09-18 |
| ES2206614T3 (es) | 2004-05-16 |
| AU709181B2 (en) | 1999-08-26 |
| HUP9903688A3 (en) | 2001-12-28 |
| JP2000506860A (ja) | 2000-06-06 |
| AU1150197A (en) | 1997-10-01 |
| BR9612552A (pt) | 1999-07-20 |
| KR19990087715A (ko) | 1999-12-27 |
| EP0946179A1 (de) | 1999-10-06 |
| EA000768B1 (ru) | 2000-04-24 |
| EA199800821A1 (ru) | 1999-02-25 |
| NO984197D0 (no) | 1998-09-11 |
| PL328948A1 (en) | 1999-03-01 |
| TR199801798T2 (xx) | 1998-12-21 |
| EP0946179A4 (de) | 2000-04-19 |
| CN1213970A (zh) | 1999-04-14 |
| IL126161A0 (en) | 1999-05-09 |
| HUP9903688A2 (hu) | 2000-03-28 |
| NO984197L (no) | 1998-11-03 |
| NZ324615A (en) | 2000-08-25 |
| DE69630055T2 (de) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69533040D1 (de) | Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien | |
| DE69428523D1 (de) | Verfahren zur behandlung von gemüts- oder geisteskrankheiten und von gemüts- oder geisteskrankheiten, die von anfällen begleitet sind | |
| DE69403969T2 (de) | Levobupivacain nützlich zur behandlung von chronischen schmerzen | |
| DE69636343D1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| DE69616376D1 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
| ATE213411T1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
| ATE258796T1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| DE59907752D1 (de) | Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien | |
| ATE145136T1 (de) | Verwendung von ketoconazol und ein retinoid zur behandlung der akne vulgaris | |
| ATE141505T1 (de) | Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht | |
| DE69713620D1 (de) | Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia | |
| DE68912195T2 (de) | Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis. | |
| DE69826023D1 (de) | Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome | |
| DE59508961D1 (de) | Verwendung von weihrauch zur behandlung der alzheimer-krankheit | |
| DE69426471T2 (de) | Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie | |
| ATE214272T1 (de) | Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz | |
| DE69630055D1 (de) | Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation | |
| DE69733169D1 (de) | Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs | |
| ATA901396A (de) | Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten | |
| ATE234613T1 (de) | Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen | |
| ATE236630T1 (de) | Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten | |
| DE69733321D1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
| DE69635282D1 (de) | Behandlung der exzessiven aggressivität mit olanzapine | |
| ATE215368T1 (de) | Verwendung von forskolin oder diese enthaltende extrakte zur herstellung eines medikaments für die behandlung von alkoholsucht | |
| DE59808106D1 (de) | Behandlung der symptome der parkinsonschen krankheit mit einem mittel enthaltend eine dopaminerge substanz und ein lokalanaesthetikum der anilid-gruppe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |